鉴定和验证肿瘤微环境相关特征，用于预测肺腺癌患者的预后和免疫治疗反应。

Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma.

机构信息

Department of Oncology, Suining Central Hospital, Suining, 629000, Sichuan, China.

Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Sci Rep. 2023 Aug 21;13(1):13568. doi: 10.1038/s41598-023-40980-2.

DOI:10.1038/s41598-023-40980-2

PMID:37604869

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10442419/

Abstract

Mounting evidence has found that tumor microenvironment (TME) plays an important role in the tumor progression of lung adenocarcinoma (LUAD). However, the roles of tumor microenvironment-related genes in immunotherapy and clinical outcomes remain unclear. In this study, 6 TME-related genes (PLK1, LDHA, FURIN, FSCN1, RAB27B, and MS4A1) were identified to construct the prognostic model. The established risk scores were able to predict outcomes at 1, 3, and 5 years with greater accuracy than previously known models. Moreover, the risk score was closely associated with immune cell infiltration and the immunoregulatory genes including T cell exhaustion markers. In conclusion, the TME risk score can function as an independent prognostic biomarker and a predictor for evaluating immunotherapy response in LUAD patients, which provides recommendations for improving patients' response to immunotherapy and promoting personalized tumor immunotherapy in the future.

摘要

越来越多的证据表明，肿瘤微环境（TME）在肺腺癌（LUAD）的肿瘤进展中起着重要作用。然而，肿瘤微环境相关基因在免疫治疗和临床结局中的作用仍不清楚。在这项研究中，鉴定了 6 个与肿瘤微环境相关的基因（PLK1、LDHA、FURIN、FSCN1、RAB27B 和 MS4A1）来构建预后模型。该模型建立的风险评分能够更准确地预测 1、3 和 5 年的预后，优于以前已知的模型。此外，风险评分与免疫细胞浸润和免疫调节基因（包括 T 细胞耗竭标志物）密切相关。总之，TME 风险评分可作为 LUAD 患者独立的预后生物标志物和免疫治疗反应的预测因子，为提高患者对免疫治疗的反应和促进未来的个体化肿瘤免疫治疗提供了建议。